Status:
COMPLETED
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Centocor, Inc.
Conditions:
Arthritis, Rheumatoid
Spondylitis, Ankylosing
Eligibility:
All Genders
18+ years
Brief Summary
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice o...
Detailed Description
The study population was chosen from a non-probability sample. The safety population consisted of all participants with at least one documented infusion of infliximab. The evaluable population consi...
Eligibility Criteria
Inclusion
- Participants treated with infliximab by rheumatologists, gastroenterologists, and dermatologists for chronic inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, or Crohn's disease.
Exclusion
- None
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
4485 Patients enrolled
Trial Details
Trial ID
NCT00727298
Start Date
February 1 2006
End Date
August 1 2011
Last Update
December 1 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.